Lunit has announced a collaboration with Daiichi Sankyo to advance research in AI‑driven biomarker discovery and translational oncology.

• Methodology: Under the collaboration, Lunit’s AI pathology platform will be used to analyse tissue slides and support the identification of predictive biomarkers.
• Research Focus: The project is intended to improve patient selection for clinical trials, with a particular emphasis on therapies such as antibody‑drug conjugates.
• Collaboration: The two companies will work together to validate and apply AI models within global drug development programmes.

This summary is based on a press release issued by Lunit.